COVID-19 may trigger or worsen refractory, or difficult-to-treat, thrombotic thrombocytopenic purpura (TTP) during the first months of pregnancy, requiring early diagnosis and aggressive treatment…
Thrombotic thrombocytopenic purpura
Thrombotic thrombocytopenic purpura is a rare, life-threatening blood disorder marked by dangerous clotting and low platelet counts. Prompt diagnosis and treatment are critical, and with proper care, most people recover and avoid serious complications.
While there’s no cure for immune thrombocytopenia, a range of treatments — from steroids to platelet-boosting therapies — can help manage symptoms. Choosing the right plan depends on platelet levels, bleeding risk, and individual health considerations.
Latest news
The preventive treatment Adzynma (recombinant human ADAMTS13) is safe and effective at reducing disease relapses for people with congenital thrombotic thrombocytopenic purpura (TTP), and…